Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. - Wikidata - awgldk - TriplyDB

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

http://www.wikidata.org/entity/Q33372761

about

Identification of a functional docking site in the Rpn1 LRR domain for the UBA-UBL domain protein Ddi1 Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma Bortezomib for the treatment of mantle cell lymphoma: an update The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis Management of mantle cell lymphoma in the elderly patient Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Trial Watch: Proteasomal inhibitors for anticancer therapy Mantle cell lymphoma: observation to transplantation The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.

P2860

Q21245310-88C1A27F-B204-4833-9907-3DE94552BFFC Q24599100-D5B9D871-FAD7-4067-8F8F-7689EF195368 Q24655119-B68FDD4A-78F4-4A93-88D5-0D0C8B3EBA2B Q26738940-9E6290E7-6A2D-4E34-9EC7-686652D6DDCE Q26772907-38E4C44F-2545-46E6-BC9C-F67A41D6B1F8 Q26776480-6718AC69-C788-45C4-89A9-B0C78C5076AF Q26783814-AA5173F6-BF9B-4B4C-9FCF-9E935AD73BD8 Q26991817-DE9C92F2-E100-4EFB-9A91-B6EF4BBCC5CC Q26999395-DE934D7B-E93B-4666-82B8-65B9EC9583D0 Q27663486-3E579223-30A2-4062-9B08-BF077364D715 Q27973422-A50112CB-9B16-4C0F-B9A1-4EDF2CF0F9EA Q28075606-443BE1A8-6555-475F-A7D0-CB92AEDAE8C4 Q28082910-92A49E93-C985-4C0F-9035-E315373B6105 Q28256317-ABC477A9-3179-40FD-B504-1BDDF55A2C0E Q30248842-5E25AD95-CBB0-4CCC-97D1-2120F94E75D1 Q30279207-6710DE2A-8FFC-42D2-8100-B1ED56FA8367 Q30358639-593523BA-7843-49E5-8C0D-845C206D8910 Q30371806-529A860D-D937-4CF6-AA24-EA3F08CE4F3A Q30456436-CE32745C-D26B-4C88-B6F7-4C6A9F7339B3 Q31164228-0A005E8E-4E41-42AA-8B55-1559E2D594CA Q33375800-D89B0A5C-A060-4061-8DBB-5CBA440058E6 Q33378902-CB767610-A189-448B-A6C4-BA7E187E7C21 Q33379949-02D0284E-CFBB-44E6-AF90-042C61C9EC1A Q33385670-8E281903-37A9-49C6-803E-2EF0B41C68B7 Q33388648-A193A14E-9B43-48DA-BC57-C16DB876C235 Q33391725-B562294C-896D-4F51-8B4A-5A786BC06988 Q33393623-49285971-E31A-45E5-B300-B7E991E82D1D Q33394153-2A3DA60B-36F0-4A71-8E18-C6CE2ADB2BBF Q33394689-73FD0013-2F56-479A-8C77-E4E6138BF0AB Q33394873-550EF377-7ABF-42D3-9B04-DFE94AB2C8B6 Q33396522-5AAE6570-AAF4-4D33-BB21-7A56AA8E9CC4 Q33398818-3059745D-AC55-47A9-AB0C-C80679B9ADF0 Q33404090-90FBDC44-10E8-48D1-AD25-33D950D0F0B4 Q33413598-BDC8ABF5-B7AE-4058-A385-4A8CD2886141 Q33414307-92D6929C-D8A8-429D-BE65-24F55D84873C Q33414603-AC5945C4-CE99-4F68-860C-29931B89D802 Q33416695-B3BB0003-9804-438F-9641-BEA0A6DBA647 Q33417803-BC3BC0F4-CF57-4728-B670-10B24D129841 Q33418257-F6A0E6E8-9434-4151-82D5-B999ED156D94 Q33420278-EC77D532-E8CE-49AE-8532-F9C4C586F951

P2860

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

http://www.wikidata.org/entity/Q33372761

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Multicenter phase II study of ...... fractory mantle cell lymphoma.

@ast

Multicenter phase II study of ...... fractory mantle cell lymphoma.

@en

type

label

Multicenter phase II study of ...... fractory mantle cell lymphoma.

@ast

Multicenter phase II study of ...... fractory mantle cell lymphoma.

@en

prefLabel

Multicenter phase II study of ...... fractory mantle cell lymphoma.

@ast

Multicenter phase II study of ...... fractory mantle cell lymphoma.

@en

P1433

Q33372761-F05DC000-7724-48C1-9225-09649F9EC1BB

P1476

Q33372761-62898A2F-DA39-482B-8287-0DDEBAF22765

P2093

Q33372761-1888D407-9D0C-44C5-9FA5-3624534C3921

Q33372761-1AB278A9-B50E-4B29-BB20-2D0378DEA452

Q33372761-234479F3-AB27-4352-9766-09F708C57570

Q33372761-62301781-D607-498B-A558-B8E640E722D1

Q33372761-6CFB9E3E-6D29-419C-8363-628ACE40F5FA

Q33372761-6EDCFD82-2CD8-4002-B7A9-6D43DEA84CF1

Q33372761-7CFADD98-8087-4984-AB4C-FC6425A3E294

Q33372761-808C90FB-1B58-46F8-9856-E71490E93FDE

Q33372761-8B4872B9-27FE-49B3-884D-481328702FCE

Q33372761-B06523C9-BAD0-43BA-9941-86B2B8692566

P304

Q33372761-5C02A4AF-008F-4CCA-A0A0-254E35A842FD

P31

Q33372761-0249522A-5FFF-401D-BBD5-D2A1C29DC2A2

P356

Q33372761-161AC16E-9034-424A-B47C-7C2D08BFD99C

P407

Q33372761-A3539035-BEC7-4420-B8D8-A1B18AED9E44

P433

Q33372761-8048CEAE-50D7-4F21-89A0-6AD4CE4BD5C3

P478

Q33372761-02252E57-29ED-4C2E-B2C4-BE0E944F3245

P50

Q33372761-12118CD2-D0DA-4B97-A430-D7EEF8C5D841

Q33372761-F3609A3D-D6D2-4EFA-9243-2E657BE73AAB

P577

Q33372761-31B21CCD-1EB3-4CED-8950-BF620A42CDCB

P698

Q33372761-D7EAD7AE-BAD8-4299-B98E-CF9B0B9B9C94

P921

Q33372761-7B990A43-43F9-43FF-B619-BF03BBC22524

P356

JCO.2006.07.9665

P1433

Journal of Clinical Oncology

P1476

Multicenter phase II study of ...... fractory mantle cell lymphoma.

@en

P2093

Amrita Krishnan

http://www.w3.org/2001/XMLSchema#string

André Goy

http://www.w3.org/2001/XMLSchema#string

Anthony L Boral

http://www.w3.org/2001/XMLSchema#string

Brad S Kahl

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Elliot Epner

http://www.w3.org/2001/XMLSchema#string

Hongliang Shi

http://www.w3.org/2001/XMLSchema#string

John P Leonard

http://www.w3.org/2001/XMLSchema#string

Michael J Robertson

http://www.w3.org/2001/XMLSchema#string

Owen A O'Connor

http://www.w3.org/2001/XMLSchema#string

P304

4867-4874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.07.9665

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin Djulbegovic

P577

2006-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17001068

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial